Skip to Main Content
Contribute Try STAT+ Today

With a final preclinical study now published, a gene therapy designed by Duke University researchers to improve treatment for the genetic disorder Pompe disease is set to enter a Phase 1 clinical trial. Now, the researchers need to raise the money to fund the trial.

Patients with Pompe disease, which affects infants and can also emerge later in life, lack or have too little of an enzyme called acid alpha-glucosidase, or GAA. GAA helps break down glycogen into fuel for cells, so without GAA, the buildup of glycogen damages muscles and leads to respiratory and heart problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I’m pretty sure I have Pompe disease – late onset. My doctor is submitting the form for the genetic testing. I have tried to learn all I can about this disease. I read about ERT and talked to Genzyme about Lumizyme, and I found that Medicare will cover it but my copay will be $1,000 mo and I will have to take it for the rest of my life – and I’m on low Social Security so that’s not an option. But I wondered if Lumizyme would address the issue of the garbage already stored in the Lysosomes – which it doesn’t. In researching this I found some information about a Gene therapy that addresses this issue and apparently only one treatment is needed. I also read about the participation of the transcription factors TFEB and TFE3 in the regulation of lysosomal function and biogenesis and there were references to treatment with something called Trehalose. I would like to learn more about these treatments and I sure would like to be part of your clinical trials or do whatever it takes to get these treatments!

  • I am 63 years old and my onset for pompe was about 7 years ago. Please inform me of any new developments on this research. Thank you. 5-1-17

  • You can call it a “ferry virus”, but viral vectors in gene therapy have proven to be anything but innocuous, especially adenoviral vectors. Study the case of Jesse Gelsinger, who received gene therapy for ornithine decarboxylase deficiency, which killed him post haste. He would still be alive today if he were simply given a protein sparing diet.

Comments are closed.